Date: 2015-03-24
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Sanofi (France)
Product: SAR425899
Action
mechanism: GLP-1R/GCGR dual agonist /glucagon-like peptide 1 (GLP-1) - Glucagon receptor (GIPR) dual agonist
Disease: type 2 diabetes
Therapeutic area: Metabolic diseases
Country: Germany
Trial
details: This randomized, double-blind, placebo-controlled studywill assess the safety and tolerability, pharmacokinetics and pharmacodynamics of repeated subcutaneous doses of SAR425899 in healthy male subjects and overweight to obese patients with type 2 diabetes mellitus. (NCT02411825)
Latest news:
